Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

Jennifer L. Guerriero(Dana-Farber Cancer Institute), Alaba Sotayo(Dana-Farber Cancer Institute), Holly Ponichtera(Dana-Farber Cancer Institute), Jessica A. Castrillon(Dana-Farber Cancer Institute), Alexandra L. Pourzia(Dana-Farber Cancer Institute), Sara Schad(Dana-Farber Cancer Institute), Shawn F. Johnson(Dana-Farber Cancer Institute), Ruben D. Carrasco(Brigham and Women's Hospital), Suzan Lazo(Dana-Farber Cancer Institute), Roderick T. Bronson(Harvard University), Scott Davis(GlaxoSmithKline (United States)), Mercedes Lobera(GlaxoSmithKline (United States)), Michael A. Nolan(GlaxoSmithKline (United States)), Anthony Letai(Dana-Farber Cancer Institute)
Nature
March 1, 2017
10.1038/nature21409
Cited by 547Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis